fig2

Figure 2. Practical workflow for liver-muscle-bone assessment and integrated management in MASLD. The figure shows a stepwise approach to liver-muscle-bone assessment in patients with MASLD. After initial evaluation of liver disease stage, cardiometabolic and renal risk, nutritional status, and treatment safety, patients are assessed for muscle health risk, vitamin D deficiency risk, and bone health risk. Low-cost screening tools include handgrip strength, SARC-F or SARC-CalF, calf circumference, gait speed, chair stand testing, fall and fracture history, and selective serum 25-hydroxyvitamin D measurement. Further assessment with DXA, BIA, CT, MRI, fracture risk assessment, or laboratory testing may be performed when screening is positive or clinical risk is high. Individualized management may include exercise, nutritional intervention, weight-loss strategies, correction of vitamin D deficiency when indicated, and bone-directed treatment. Functional follow-up and periodic reassessment should guide treatment adjustment according to liver disease stage, muscle reserve, bone health, metabolic risk, safety, and patient preference. BIA: Bioelectrical impedance analysis; CT: computed tomography; DXA: dual-energy X-ray absorptiometry; MASLD: metabolic dysfunction-associated steatotic liver disease; MRI: magnetic resonance imaging; PTH: parathyroid hormone; T2DM: type 2 diabetes mellitus.